Tag Archives: coronary angioplasty

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization.  The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab

AHA 2020 | El riesgo aumenta cuando los operadores no “escuchan” al FFR

AHA 2020 | The More Operators “Listen” to FFR, the Lower the Risk

When operators decide to proceed with PCI despite a negative FFR (fairly frequent in the daily practice) outcomes at 5 years are far worse. This information comes from a large Canadian register presented at AHA 2020 Scientific Sessions, simultaneously published in JAMA. PCI to a non-ischemic lesion results in increased events risk at long term,

Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues

Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to

TCT 2020 | Our Next Goal Should Be Using IVUS Guidance in Every Angioplasty

The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv. At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by

TCT 2020 | Nueva información sobre el valor del FFR antes y después de la angioplastia

TCT 2020 | Fewer Symptoms and Events when Optimizing with iFR

Symptomatic patients undergoing PCI with no residual ischemia confirmed by iFR have superior symptom improvement at one year vs. patients who did not receive the optimization.  In addition to symptoms, patients receiving iFR optimization (final value ≥ 0.95) presented lower cardiac mortality, spontaneous MI or clinically justified revascularization vs. patients with <0.95 final value.  

perforación coronaria en angioplastia

Complex PCI: Complex Characteristics Impact Results

Patients with a bigger number of complex anatomical characteristics that increase PCI complexity have worse results at one-year followup. These data come from a large multicenter study (e-Ultimaster) recently published in EuroIntervention. The more complex the characteristics, the greater the increase in events.  It is important to see past the obvious anatomical challenges (bifurcations, calcification,

ESC 2020 | At Long Term, Diabetic Patients Benefit from Surgery

Data of this “real world” study have confirmed that diabetic patients with multivessel disease will benefit from coronary artery bypass grafting (CABG).  According to Dr. Douglas S. Lee, main author of this study, the evidence is fairly conclusive, enough to recommend CABG as first option in this particular subgroup of patients similar to FREEDOM patients. 

ESC 2020 | Trimetazidina post angioplastia: sin efectos adversos pero sin grandes beneficios

ESC 2020 | Post PCI Trimetazidine: No Adverse Events or Great Benefits

Trimetazidine in addition to optimal medical therapy in patients undergoing coronary PCI does not change events rate at long term.  The ATPCI study was presented at ESC 2020 and simultaneously published in the Lancet. This study randomized coronary PCI patients with stable or acute NSTEMI coronary syndromes to trimetazidine vs. placebo.   What is the rationale

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without an increase in thrombotic events. This is also the case for patients admitted with acute coronary syndrome. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major events compared with

¿Son los stents con polímero bioabsorbible más trombogénicos que los de segunda generación con polímero durable?

ISAR-TEST-5: 10 años de los DES con polímero vs sin polímero

After 10 years, unstable or chronic coronary patients revascularized with drug-eluting stents (DES) had similar, very good outcomes regardless of whether the DES did or did not have a polymer, according to the ISAR-TEST-5 study, recently published in J Am Coll Cardiol. The 10-year device-oriented endpoints occurred in 43.8% of patients treated with a polymer-free sirolimus-eluting